Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.49 |
| ▸ | LIPE | Q05469 | 4/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574801 | 0.89 | LIPE (0.51) | EPHX2LIPETRPV1POLBCYP2C9 | |
| SCHEMBL1574964 | 0.88 | BACE1 (0.49) | EPHX2LIPETRPV1POLBCYP2C9 | |
| SCHEMBL1574888 | 0.88 | LMNA (0.52) | EPHX2LIPETRPV1POLBCYP2C9 | |
| SCHEMBL1575220 | 0.87 | MAPT (0.57) | EPHX2LIPETRPV1CYP2C9CYP2C19 | |
| SCHEMBL1574999 | 0.87 | EPHX2 (0.53) | EPHX2LIPECYP2C9CYP2C19MAPT | |
| SCHEMBL1574384 | 0.86 | LIPE (0.47) | EPHX2LIPETRPV1CYP2C9CYP2C19 | |
| SCHEMBL1574795 | 0.86 | LIPE (0.61) | EPHX2LIPETRPV1POLBCYP2C9 | |
| SCHEMBL1574301 | 0.85 | LIPE (0.54) | EPHX2LIPETRPV1POLBCYP2C9 | |
| SCHEMBL1575480 | 0.85 | MAPT (0.57) | EPHX2LIPETRPV1CYP2C9CYP2C19 | |
| SCHEMBL1575426 | 0.85 | LMNA (0.49) | EPHX2LIPECYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765783-B2 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | ONO PHARMACEUTICALS CO., LTD. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-1522314-B1 | REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION | ONO PHARMACEUTICAL CO (JP) | 2014-03-05 | — | — | EP | disclosed |
| EP-2508204-A2 | Remedies for diseases caused by vascular contraction or dilation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-10 | — | — | EP | disclosed |
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20060148844-A1 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | ONO PHARMACEUTICAL CO., LTD | 2006-07-06 | — | — | US | disclosed |
| EP-1522314-A1 | REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | EPHX2 489/4885LIPE 295/4885TRPV1 1741/4885 |
| US-20060148844-A1 | Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation | EDNRA, EDNRB, CACNG5 | EPHX2 1078/4885LIPE 2110/4885TRPV1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.